前沿速览024期| CAR-T治B淋 前沿览新知
01
美国淋巴瘤CAR-T联盟研究：大B细胞淋巴瘤标准治疗方案Axicabtagene Ciloleucel的五年随访结果
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
第一作者：Jain MD
J Clin Oncol (IF=42.1). 2024 Aug 2:JCO2302786.
全文网址：https://ascopubs.org/doi/10.1200/JCO.23.02786?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
大B细胞淋巴瘤患者经CD19 CAR-T治疗后严重CRS和ICANS的新型预后评分系统
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
第一作者：Sesques P
J Hematol Oncol (IF=29.5). 2024 Aug 6;17(1):61.
全文网址：https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01579-w
03
提升CAR-T细胞治疗淋巴瘤的疗效
Boosting CAR T cells against lymphomas
第一作者：Pabst T
Blood (IF=20.0). 2024 Aug 15;144(7):689-691.
全文网址：https://ashpublications.org/blood/article/144/7/689/517284/Boosting-CAR-T-cells-against-lymphomas
04
CD19/20双靶点CAR-T细胞治疗复发/难治性B细胞非霍奇金淋巴瘤患者的I/II期临床试验
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
第一作者：Wang L
Blood Cancer J (IF=12.9). 2024 Aug 7;14(1):130.
全文网址：https://www.nature.com/articles/s41408-024-01105-8
05
预处理前大B细胞淋巴瘤微环境中PD-L1阳性巨噬细胞和肿瘤细胞的丰度及其与T细胞的接近程度对CD19 CAR-T细胞免疫疗法疗效的影响
PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy
第一作者：Hirayama AV
Hemasphere (IF=7.6). 2024 Aug 7;8(8):e142.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303978/
06
增加Axicabtagene Ciloleucel的可及性对健康的影响：西班牙案例研究
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain
第一作者：Córdoba R
Cancers (Basel) (IF=4.5). 2024 Jul 30;16(15):2712.
全文网址：https://www.mdpi.com/2072-6694/16/15/2712
07
CAR-T细胞疗法受试者的巨细胞病毒感染：以肿瘤学结果为重点的观察性研究
Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes
第一作者：Khawaja F
Open Forum Infect Dis (IF=3.8). 2024 Jul 18;11(8):ofae422.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289494/
08
骨髓瘤和淋巴瘤CAR-T细胞疗法在全球实施的障碍
Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma
第一作者：Medina-Olivares FJ
Front Oncol (IF=3.5). 2024 Jul 19;14:1397613.
全文网址：https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1397613/full
09
CD19 CAR-T细胞疗法作为复发/难治性弥漫大B细胞淋巴瘤二线治疗的系统综述和荟萃分析
A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma
第一作者：Asghar K
Front Oncol (IF=3.5). 2024 Jul 18;14:1407001.
全文网址：https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1407001/full
10
在接受CAR-T治疗的复发/难治性大B细胞淋巴瘤患者中收集纵向患者报告结局的可行性
Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
第一作者：Balitsky A
BMC Cancer (IF=3.4). 2024 Aug 9;24(1):984.
全文网址：https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12574-2
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.8-16 valid until 2026.8
供稿与审核：临床开发与医学部